Dextromethorphan: Neuropathy

Abstract

Off-Label Drug Uses

This Hospital Pharmacy feature is extracted from Off-Label DrugFacts, a quarterly publication available from Facts and Comparisons. Off-Label DrugFacts is a practitioner-oriented resource for information about specific FDA-unapproved drug uses. This new guide to the literature will enable the health care professional/clinician to quickly identify published studies on off-label uses and to determine if a specific use is rational in a patient care scenario. The most relevant data are provided in tabular form so that the reader can easily identify the scope of information available. A summary of the data—including, background, study design, patient population, dosage information, therapy duration, results, safety, and therapeutic considerations—precedes each table of published studies. references direct the reader to the full literature for more comprehensive information prior to patient care decisions.

Get full access to this article

View all access options for this article.

References

McQuay

, et al. Dextromethorphan for the treatment of neuropathic pain: A double blind randomised controlled crossover trial with integral n-of-1 design. Pain. 1994; 59:127–33.

Nelson

, et al. High dose oral dextromethorphan versus placebo in painful diabetic neuropathy and postherpetic neuralgia. Neurology. 1997; 48:1212–8.

Belec

, et al. Extensive oxidative metabolism of dextromethorphan in patients with alimitrine neuropathy. Br J Clin Pharmacol. 1989;27:3 87–90.

Criner

, Perdun

CS.

Dextromethorphan and diabetic neuropathy.

Ann Pharmacotherapy. 1999;33:1221–3.

Price

et al. The N-methyl-Daspartate receptor antagonist dextromethorphan selectively reduces temporal summation of second pain in man. Pain. 1994;59:165–74.